By Sheeba M. | May 17, 2026
MSOs Report Profitable Q1 2026 Amid Historic Schedule III Reclassification
The Trump administration’s April 28 reclassification of medical marijuana to Schedule III triggered an immediate wave of strong earnings from leading multi-state operators. Trulieve, Curaleaf, and Green Thumb Industries all posted Q1 2026 results that underscored both the immediate tax relief benefit and the strategic positioning winners will enjoy in the post-Schedule III landscape.
The Big Three Report Strong Q1 Numbers
Trulieve ($TCNNF) posted Q1 2026 revenue of $287 million with a 59% gross margin—up from 62% in Q1 2025—generating $100 million in Adjusted EBITDA (35% margin) and positive GAAP net income of $2 million. The company operates 240 dispensaries and over 4 million square feet of cultivation capacity. CEO Kim Rivers emphasized the company’s scale and market position: “With 206 dispensaries and over 3.5 million square feet of production serving medical patients, Trulieve is well positioned to explore new opportunities enabled by rescheduling.”
Curaleaf Holdings ($CURLF) reported Q1 2026 net revenue of $324.2 million (up 6% YoY) with international revenue surging 35% to $47 million. The company posted GAAP net income of $70.1 million ($0.09 per share) and Adjusted EBITDA of $63.4 million at a 19.6% margin. During the quarter, Curaleaf completed the buyout of the remaining 45% equity interest in its German subsidiary Four20 Pharma, taking full ownership. Chairman Boris Jordan called the reclassification “historic,” noting that macro headwinds are turning into tailwinds.
Green Thumb Industries ($GTBIF) reported Q1 2026 revenue of $300.2 million (up 7.4% YoY) with GAAP net income of $15.4 million ($0.07 per share) and normalized EBITDA of $93.5 million at a 31.2% margin. The company generated $76 million in cash flow from operations and repurchased approximately 6 million subordinate voting shares for $33.3 million during the quarter.
280E Tax Relief Reshapes MSO Economics
The most consequential change for cannabis investors is the removal of Internal Revenue Code Section 280E, which previously disallowed standard business deductions for state-licensed medical cannabis operators. The IRS announced a transition rule making the reclassification retroactive to January 1, 2026 for calendar year taxpayers.
Pre-rescheduling, cannabis operators faced effective federal tax rates of 70% to 75% because 280E disallowed wages, rent, marketing, and depreciation. For state-licensed medical operators, those deductions are now available, potentially pushing effective rates closer to the standard corporate 21% rate. For operators like Trulieve, Curaleaf, and Green Thumb with significant medical revenue (60% for Jushi, for example), the earnings accretion in H2 2026 could be material.
Jushi Holdings Delivers 4% Growth with Strong Margin Expansion
Jushi Holdings ($JUSHF) reported Q1 2026 revenue of $66.4 million (up 4% YoY) with impressive gross profit margin expansion of 460 basis points to 45.0%. The company benefited from improved operational performance at its grower-processor network, with wholesale growth driven by Massachusetts and Ohio. Jushi expanded its retail footprint with new dispensaries in Cincinnati, Ohio. Medical sales represent approximately 60% of revenue, positioning the company to immediately capture 280E relief benefits.
Jushi also strengthened its balance sheet by refinancing $132.3 million in prior debt, securing improved terms and extending maturities while preserving balance sheet flexibility.
DEA Hearing June 29: The Next Catalyst
While immediate 280E relief applies to medical operations, the critical next catalyst is the DEA’s expedited administrative hearing beginning June 29, 2026 to consider whether marijuana—including adult-use—should move to Schedule III. If approved, 280E relief would extend to recreational operations, eliminating the critical tax barrier that has constrained profitability for dual-license MSOs.
Interested parties had to submit written notice of participation by May 28, with the DEA notifying selected participants on June 22. A final rule could be published as soon as late 2026, though litigation could extend the timeline.
Investor Takeaway
Multi-state operators with strong cash generation, disciplined capital allocation, and meaningful medical revenue mix are best positioned to capture the immediate 280E benefit. Track operator quality, balance sheet strength, and exposure to state-licensed medical markets. The June 29 hearing will determine whether recreational operations get the same tax relief—a catalyst that could reshape the entire sector’s profitability profile.
Sources
- Investorideas.com – Cannabis Stocks in Focus as 280E Relief Lands and MSOs Post Profitable Q1 2026 Results – Comprehensive earnings overview and 280E analysis
- PR Newswire – Trulieve Q1 2026 Results – Official earnings and DEA registration update
- Globe Newswire – Jushi Holdings Q1 2026 Results – Margin expansion and refinancing details
Related Articles
Track cannabis stocks with the Weedstock Real-Time Tracker